Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ocular Therapeutix, Inc.

Home Clinical Trial Sponsors and OrganizationsOcular Therapeutix, Inc.

Ocular Therapeutix, Inc.

ACTIVE

Ocular Therapeutix

24 Crosby Dr, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.ocutx.comPublic267 employeesEstablished: 2006-01-01$1.4B

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

34

3 active

Approvals

2

Total approvals

Agencies

1

Regulatory bodies

Founded

2006

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

15

44.1%

Phase 1

7

20.6%

Phase 2

7

20.6%

Early Phase 1

1

2.9%

Not Applicable

1

2.9%

Trial Status Distribution

Active, not recruiting

3

8.8%

Completed

24

70.6%

Recruiting

4

11.8%

Terminated

1

2.9%

Unknown

1

2.9%

Withdrawn

1

2.9%

Clinical Trials

Trials sponsored by this organization (34)

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Apr 2026850 participants

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Nov 2025930 participants

To test the effectiveness and safety of sponsor product of Intravitreal OTX-TKI (Axitinib Implant) in cases of Neovascular Age- Related Macular Degeneration

May 2025825 participants

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Active, not recruiting

Nov 2024825 participants

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Active, not recruiting

Jan 2024344 participants

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

May 2023100 participants

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Active, not recruiting

Jan 202321 participants

An Observational, Qualitative Study Assessing Eye Drop Administration

Apr 2022300 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

2

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials34
Approvals2
News

Back to Organizations